Save the date: TBVI Symposium Les Diablerets 2024
We are delighted to announce that TBVI will once again organize its annual meeting in the Swiss mountains of Les Diablerets from 30-31 January 2024. TB vaccine researchers, developers, funders and policymakers in TBVI’s network will gather together to be updated on the latest developments in the field and to exchange new ideas. We would be […]
TBVI Young Scientist Award 2023-2024
Would you like to present your work at the TBVI Annual Symposium? To encourage talented young scientists and recognise outstanding contributions to TB vaccine research and development, TBVI presents the TBVI Young Scientist Awards. Young scientists are given the opportunity to present their work during the annual TBVI symposium where researchers, policy makers and funders […]
TBVI Governance Board Communiqué
TBVI Governance Board Communiqué Tuberculosis (TB) is a major unsolved global health problem. Novel vaccines against TB will be critical tools to ultimately end this silent pandemic. TBVI and its partners are key actors in the effort to research and develop novel TB vaccines. The TuBerlculosis Vaccine Initiative (TBVI) Governance Board would like to announce […]
First progress meeting MTBVACN3
From 15-18 May 2023, the first annual progress meeting of the MTBVAC phase III clinical trial EDCTP co-funded project took place in Andasibe and Antananarivo, Madagascar. The consortium, composed of nine partners in total of which six recruiting sites (four in South Africa, one in Senegal and one in Madagascar), informally and formally discussed the […]
Start ITHEMYC
The Horizon Europe programme has funded the ITHEMYC project to establish a critical path for selection of promising innovative adjunct TB immunotherapies and progress 2 of these immunotherapies to completion of preclinical proof of concept. Read more about the project and its partners.
TBVAC-HORIZON kicks off
The Horizon Europe programme has funded the TBVAC-HORIZON project to improve the understanding of lung immunity to tuberculosis infection and to establish a diversified innovative TB vaccine pipeline targeting mucosal immunity. TBVAC-HORIZON, consisting of 19 partners, will be coordinated by TBVI and will run for 4 years. To read more about the project, follow the […]
Joint meeting of EDCTP-funded TB vaccine projects
The four EDCTP-funded late-stage TB vaccine development projects: POR TB Consortium, priMe and MTBVAC-Newborns Phase 2a and MTBVACN3, meet on a regular basis to exchange knowledge and experiences. This year’s meeting, organised by TBVI, took place on 5 April 2023 in a hybrid way, with some project partners present in Les Diablerets in Switzerland where […]
Kick off MTBVAC Phase III in newborns
From 10-12 May 2022, the Kick-off Meeting (KoM) of the MTBVAC phase III clinical trial EDCTP co-funded project was held in Baiona, Spain. With the only licensed TB vaccine, Bacillus Calmette-Guérin (BCG), having limited impact on prevention of TB disease and transmission of Mycobacterium tuberculosis, there is an urgent need for a new, improved TB vaccine. […]
2019 TBVI Symposium “TB Vaccines: Global Collaboration and Recent Advances in the Field”.
From 28th to 31st January 2019 in Les Diablerets Switzerland, the TBVI symposium and TBVAC2020 annual meeting brought together 120 scientists and policy makers from 70 research institutes, universities, industry, funding agencies, technical agencies from 17 countries. The meeting provided the opportunity to hear from key global stakeholders about their current activities in the field […]